flecainide has been researched along with Andersen Cardiodysrhythmic Periodic Paralysis in 12 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This multicenter study suggests that oral flecainide therapy is an effective and safe means of suppressing VAs in patients with ATS with KCNJ2 mutations, though the U-wave amplitude remained unchanged by flecainide." | 2.80 | Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations. ( Aiba, T; Anzai, T; Hayashi, H; Horie, M; Ishibashi, K; Ishihara, M; Kamakura, S; Kimura, H; Kusano, K; Miyamoto, K; Miyamoto, Y; Nakajima, I; Noda, T; Ogawa, H; Ohno, S; Okamura, H; Shimizu, W; Tanioka, Y; Tsuboi, I; Tsuchiya, T; Yasuda, S; Yasuoka, C; Yoshida, Y, 2015) |
| "Flecainide was added to the treatment regime." | 1.48 | Can flecainide totally eliminate bidirectional ventricular tachycardia in pediatric patients with Andersen-Tawil syndrome? ( Ergül, Y; Onan, SH; Özgür, S; Tuzcu, V, 2018) |
| "Bidirectional ventricular tachycardia (BVT), although a rare arrhythmia in the general population, is frequently observed in patients with Andersen-Tawil syndrome and long QT interval." | 1.35 | Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome. ( Gonzalez, MD; Kalaizich, L; Pellizzón, OA; Ptácek, LJ; Tristani-Firouzi, M, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheung, CC | 1 |
| Scheinman, M | 1 |
| Lee, BK | 1 |
| Ünal Yüksekgönül, A | 1 |
| Azak, E | 1 |
| Akalın, A | 1 |
| Ertuğrul, İ | 1 |
| Kılıç, E | 1 |
| Utine, GE | 1 |
| Karagöz, T | 1 |
| Rujirachun, P | 1 |
| Junyavoraluk, A | 1 |
| Pithukpakorn, M | 1 |
| Suktitipat, B | 1 |
| Winijkul, A | 1 |
| Fernández, M | 1 |
| Marín, MDR | 1 |
| Fernández-Armenta, J | 1 |
| Mora-López, F | 1 |
| Fernández Rivero, R | 1 |
| Berruezo, A | 1 |
| Cano Calabria, L | 1 |
| Vázquez García, R | 1 |
| Ergül, Y | 1 |
| Özgür, S | 1 |
| Onan, SH | 1 |
| Tuzcu, V | 1 |
| Sato, A | 1 |
| Takano, T | 1 |
| Chinushi, M | 1 |
| Minamino, T | 1 |
| Janson, CM | 1 |
| Poelzing, S | 1 |
| Shah, MJ | 1 |
| Hayashi, H | 3 |
| Kawaguchi, T | 1 |
| Horie, M | 2 |
| Miyamoto, K | 1 |
| Aiba, T | 1 |
| Kimura, H | 1 |
| Ohno, S | 1 |
| Yasuoka, C | 1 |
| Tanioka, Y | 1 |
| Tsuchiya, T | 1 |
| Yoshida, Y | 1 |
| Tsuboi, I | 1 |
| Nakajima, I | 1 |
| Ishibashi, K | 1 |
| Okamura, H | 1 |
| Noda, T | 1 |
| Ishihara, M | 1 |
| Anzai, T | 1 |
| Yasuda, S | 1 |
| Miyamoto, Y | 1 |
| Kamakura, S | 1 |
| Kusano, K | 1 |
| Ogawa, H | 1 |
| Shimizu, W | 1 |
| Barajas-Martinez, H | 1 |
| Hu, D | 1 |
| Ontiveros, G | 1 |
| Caceres, G | 1 |
| Desai, M | 1 |
| Burashnikov, E | 1 |
| Scaglione, J | 1 |
| Antzelevitch, C | 1 |
| Bökenkamp, R | 1 |
| Wilde, AA | 1 |
| Schalij, MJ | 1 |
| Blom, NA | 1 |
| Pellizzón, OA | 1 |
| Kalaizich, L | 1 |
| Ptácek, LJ | 1 |
| Tristani-Firouzi, M | 1 |
| Gonzalez, MD | 1 |
1 review available for flecainide and Andersen Cardiodysrhythmic Periodic Paralysis
| Article | Year |
|---|---|
Successful treatment of arrhythmia with β-blocker and flecainide combination in pregnant patients with Andersen-Tawil syndrome: A case report and literature review.
Topics: Adrenergic beta-Antagonists; Adult; Andersen Syndrome; Anti-Arrhythmia Agents; Female; Flecainide; H | 2021 |
1 trial available for flecainide and Andersen Cardiodysrhythmic Periodic Paralysis
| Article | Year |
|---|---|
Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations.
Topics: Administration, Oral; Adolescent; Adult; Andersen Syndrome; Anti-Arrhythmia Agents; Electrocardiogra | 2015 |
10 other studies available for flecainide and Andersen Cardiodysrhythmic Periodic Paralysis
| Article | Year |
|---|---|
A peculiar case of palpitations and syncope.
Topics: Andersen Syndrome; Arrhythmias, Cardiac; Flecainide; Humans; Mutation; Syncope | 2022 |
Efficacy of flecainide in bidirectional ventricular tachycardia and tachycardia-induced cardiomyopathy with Andersen-Tawil syndrome.
Topics: Adolescent; Andersen Syndrome; Cardiomyopathies; Child; Female; Flecainide; Humans; Tachycardia; Tac | 2022 |
Response to flecainide test in Andersen-Tawil syndrome with incessant ventricular tachycardia.
Topics: Adult; Andersen Syndrome; Anti-Arrhythmia Agents; Diagnosis, Differential; Electrocardiography; Fema | 2018 |
Can flecainide totally eliminate bidirectional ventricular tachycardia in pediatric patients with Andersen-Tawil syndrome?
Topics: Adolescent; Andersen Syndrome; Anti-Arrhythmia Agents; Child; Female; Flecainide; Humans; Tachycardi | 2018 |
Usefulness of the intravenous flecainide challenge test before oral flecainide treatment in a patient with Andersen-Tawil syndrome.
Topics: Administration, Intravenous; Administration, Oral; Adult; Andersen Syndrome; Anti-Arrhythmia Agents; | 2019 |
Combined inhibition of Na⁺ and Ca²⁺ channels: a novel paradigm for the treatment of incessant ventricular arrhythmias in Andersen-Tawil syndrome.
Topics: Adolescent; Andersen Syndrome; Arrhythmias, Cardiac; Calcium Channel Blockers; Electrocardiography, | 2014 |
Effect of flecainide on T-wave alternans in Andersen-Tawil syndrome.
Topics: Andersen Syndrome; Anti-Arrhythmia Agents; Atenolol; Drug Therapy, Combination; Electrocardiography; | 2014 |
Biophysical and molecular characterization of a novel de novo KCNJ2 mutation associated with Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia mimicry.
Topics: Amino Acid Sequence; Amino Acid Substitution; Andersen Syndrome; Arrhythmias, Cardiac; Base Sequence | 2011 |
Flecainide for recurrent malignant ventricular arrhythmias in two siblings with Andersen-Tawil syndrome.
Topics: Andersen Syndrome; Anti-Arrhythmia Agents; Child; Child, Preschool; Defibrillators, Implantable; Fem | 2007 |
Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome.
Topics: Adolescent; Andersen Syndrome; Anti-Arrhythmia Agents; Cardiomyopathies; Female; Flecainide; Humans; | 2008 |